Orient Pharma Co., Ltd. (TPEX:4166)
Taiwan · Delayed Price · Currency is TWD 26.15
+1.30 (5.23%)
Dec 31, 2025, 1:30 PM CST
Orient Pharma Market Cap
Orient Pharma has a market cap or net worth of 6.36 billion as of December 31, 2025. Its market cap has decreased by -23.71% in one year.
Market Cap
6.36B
Enterprise Value
6.01B
Revenue
1.28B
Ranking
n/a
PE Ratio
46.05
Stock Price
26.15
Market Cap Chart
Since June 15, 2012, Orient Pharma's market cap has increased from 4.12B to 6.36B, an increase of 54.41%. That is a compound annual growth rate of 3.26%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 31, 2025 | 6.36B | -20.85% |
| Dec 31, 2024 | 8.03B | 80.00% |
| Dec 29, 2023 | 4.46B | 14.13% |
| Dec 30, 2022 | 3.91B | 11.76% |
| Dec 30, 2021 | 3.50B | 28.52% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 238.84B |
| PharmaEssentia | 173.83B |
| Lotus Pharmaceutical | 74.42B |
| Heron Neutron Medical | 70.42B |
| Bora Pharmaceuticals Co., LTD. | 60.90B |
| Lin BioScience | 33.13B |
| Lumosa Therapeutics | 31.84B |
| Center Laboratories | 31.06B |